Clinical Research Directory

Inclusion Criteria: 1. Age ≥ 18 years. 2. Able to provide written informed consent. 3. Clinical suspicion of cirrhosis evaluated in the last six months preceding the recruitment into the study. The presence of clinical suspicion is at the discretion of the (referring) clinician. For reference this will typically be based on (a combination of) the following: * Risk factors: viral hepatitis, metabolic dysfunction associated steatotic liver disease (MASLD), alcoholic liver disease, primary biliary cholangitis, primary sclerosing cholangitis, autoimmune hepatitis, haemochromatosis or combinations of these diseases * Symptoms: e.g. fatigue, weakness, abdominal pain, nausea, vomiting, loss of appetite, oedema, jaundice, spider angioma, palmar erythema, clubbing, gastrointestinal bleeding or altered blood parameters in a liver function test. Exclusion Criteria: 1. Interventional treatment for (underlying cause of) cirrhosis aimed at disease modification during the past six months. Any treatment solely focused on symptom/complications management are permissible. 2. Received an investigational medicinal product in the context of a Clinical Trial (CTIMP) during the 28 days prior to administration of the (first) probe. 3. Women who are pregnant or breastfeeding, for women of childbearing potential a urine pregnancy test can be administered 4. Known allergy/intolerance to any of the constituents of the EVOC-probe cocktail, specifically limonene, 2-butanol, 2-pentanone, polysorbate 80 (aka Tween-80), and sucralose. 5. Subjects on peritoneal- or hemo-dialysis 6. Primary referral for evaluation of the presence of liver cancer (e.g. abnormal findings on imaging). 7. The presence of histopathologically diagnosed liver cancer. 8. (Anticipated) inability to complete the breath sampling procedure due to e.g., inability to maintain adequate ventilation unaided / Inability to comply with the study procedures in the opinion of the investigator.